Pyxis Oncology, Inc. (PYXS)

Market Cap	70.20M
Revenue (ttm)	n/a
Net Income (ttm)	-98.92M
Shares Out	43.87M
EPS (ttm)	-2.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	210,624
Open	1.72
Previous Close	1.74
Day's Range	1.54 - 1.74
52-Week Range	1.10 - 6.92
Beta	n/a
Analysts	Strong Buy
Price Target	12.00 (+650.0%)
Earnings Date	Oct 31, 2023

About PYXS

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and he...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 1, 2021
• Employees: 72
• Stock Exchange: NASDAQ
• Ticker Symbol: PYXS

Analyst Forecast

According to 3 analysts, the average rating for PYXS stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 650.00% from the latest price.

Price Target

$12.0

(650.00% upside)

Analyst Consensus: Strong Buy